NEWS & MEDIA

NEOVACS SIGNS A COOPERATION AGREEMENT WITH THE DEPARTMENT IMMUNOLOGY OF DIABETES AT THE REPUTED HOSPITAL COCHIN IN PARIS

To collaborate on development of new diabetes treatment using Neovacs’ Kinoid Technology

Paris, October 12, 2016 – NEOVACS (Alternext Paris: ALNEV PEA-PME eligible), a leader in active immunotherapies for the treatment of autoimmune diseases, today announceda collaboration with Doctor Agnès Lehuen and Professor Christian Boitard, who are leading the laboratory for Research in Immunology of Diabetes at the reputed Cochin Hospital in Paris. The goal of this collaboration is to achieve proof of concept for the use of Neovacs’ IFNa Kinoid in the treatment of Type 1 diabetes.

 

As part of this collaboration, Doctor Lehuen and Professor Boitard’s teams will jointly conduct research with scientists from Neovacs on INFa Kinoid in NOD models (Non-Obese Diabetic mice – the most relevant mouse model for this disorder). Existing scientific publications offer a significant body of evidence to support the involvement of IFNa in Type 1 diabetes[1]. This preclinical study aims to determine whether the use of the IFNa Kinoid vaccine can control this disorder by producing polyclonal neutralizing antibodies to Interferon alpha.

 




[1] Cf. Publications scientifiques :

Meyer et al., 2016, Cell 166, 582–595, July 28, 2016

Ferreira et al., Diabetes Volume 63, July 2014

Diana et al., Nature Medicine Volume 19, January 2013